Navigation Links
PPD Announces Plan to Repurchase Shares of its Common Stock
Date:2/20/2008

WILMINGTON, N.C., Feb. 20 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced its plans to begin a stock repurchase program whereby up to $350 million of its common stock may be purchased from time to time in the open market.

The company made the decision to initiate a share repurchase program in view of the current price at which the company's stock is trading, the strength of the company's balance sheet and its ability to generate cash, as well as to minimize earnings dilution from future equity issuances, including stock option exercises, purchases under the company's employee stock purchase plan and other equity compensation awards.

"The board of directors has evaluated potential stock repurchase programs in the past, and now believes that this repurchase plan is appropriate and a good use of a portion of our capital at the present time," said Fred Eshelman, chief executive officer of PPD. "It reflects the strength of the company's financial position, our confidence in the future potential of PPD and our continuing commitment to maximize value for our shareholders."

The company expects to finance the share repurchases from existing cash on hand and cash generated from future operations.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com .

Except for historical informati
'/>"/>

SOURCE PPD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 /PRNewswire-iReach/ -- A case study from Intel ... school,s bioengineering department and the Intel® Internet of ... Academic Program, UCSD,s research focuses on exploring the ... Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... of Dr. Todd P. Coleman , Associate ...
(Date:8/20/2014)... 20, 2014 WriteResult®, a leading provider ... it has expanded its myPROpad™ ePRO tablet with the ... one of the most widely used and well-respected Patient ... status. The EQ-5D is used during clinical trials and ... that can be used to demonstrate Health-Related Quality of ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2EQ-5D™ Assessment Now Available for iPad 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... Toronto Stock Exchange Symbol: MS , ... EDMONTON, AB , ... today announced its updated corporate strategy. The Company,s new strategy ... industry, whereby BioMS will directly invest in and advise companies ...
... , May 3 The Global Alliance for ... the 2010 BIO International Convention that they have entered into ... clinical use of drugs against tuberculosis (TB), including drug resistant ... are resistant to at least one of today,s standard first-line ...
... , WALTHAM, Mass. , May 3 Interleukin ... Lewis H. Bender will moderate and co-present a panel ... Development: How to Improve Efficacy and Commercial Success" at the BIO ... Chicago, IL.  The panel discussion will be held Wednesday, ...
Cached Biology Technology:BioMS updates corporate strategy and adds leading healthcare investment banker 2BioMS updates corporate strategy and adds leading healthcare investment banker 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Interleukin Genetics to Present at Upcoming Biotech Industry Meetings 2
(Date:8/21/2014)... team of researchers at Louisiana Tech University ... affordable, consumer-grade 3D printers and materials to ... antibacterial and chemotherapeutic compounds for targeted drug ... students and research faculty from Louisiana Tech,s ... to create filament extruders that can make ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... (HCI) at the University of Utah have identified and ... the unregulated enzyme driving the blood cancer chronic myeloid ... 6,000 new cases of CML will be diagnosed in ... inhibitors (TKIs), target BCR-ABL and are effective at controlling ... it in a way that allows patients to get ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... an iron storage molecule in the cell can serve ... gene therapy may use a technique in which non-invasive ... molecule. The results of this research, conducted by Prof. ... were published in the research journal Neoplasia. , Neeman, ...
... at Washington University in St. Louis has shown that ... sexual organs, and actually choose them for mating. That ... called a gonopodium. These fish out-compete the larger-endowed males ... burst speed than the males with larger genitalia, who ...
... show that stem cell therapy can be used effectively to ... two months, stem cells harvested from another pig's bone marrow ... and repaired damaged heart muscle by 50 percent to 75 ... the 2004 Scientific Sessions of the American Heart Association, are ...
Cached Biology News:Novel live reporting system to track cells 2IMF Launches World’s First DNA Database for Myeloma Patients 2IMF Launches World’s First DNA Database for Myeloma Patients 3IMF Launches World’s First DNA Database for Myeloma Patients 4Stem cell therapy successfully treats heart attack in animals 2
... high-performance pump, available in a single and twin ... valve design. With the most compact, lightweight package ... use in portable air and gas applications., ... and T2-01TH). , Delivers 1.5 and 2.0 liters ...
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
... RNA Spike-In Kit contains in vitro synthesized, ... complementary control probes on Agilents microarrays, with ... as a positive microarray control in the ... kit is a required component of the ...
... Protein Purification System provides a simple, ... purification of glutathione-S-transferase (GST) fusion proteins. ... are used to isolate GST-tagged protein ... lysate using either a manual (requires ...
Biology Products: